Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous diclofenac dose-finding for acute migraine attack
2017-004828-29Phase 2Completed
- Sponsor
- IBSA Group
- Start
- Nov 2020
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of diclofenac HPBCD in migraine (4 arms), sponsored by IBSA Group. Primary endpoint: Pain freedom at 2 hours. Started Nov 2020; status: completed.
02
Drugs
diclofenac HPBCD
03
Conditions
migraine
Beyond the preview
Go deeper on 2017-004828-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004828-29.